June 2, 2025 KAHR Bio Announces Positive Phase 2 Results of DSP107 in Combination with anti-PD-L1 in Colorectal Cancer Cision PR Newswire View Article
May 31, 2023 KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors View Article
November 18, 2022 MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma View Article
February 17, 2022 KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers View Article
